Of the 2,100 entries from across the globe, 87 extraordinary photos were recognized for their originality, technique, and impact. They included the pink and purple hues of an electrical arc ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

‘Raised roads, walls and T junctions all over it. Structures inside walled compounds,’ he added, pointing to high-quality ...

Looking back on the NBA’s 75 Years in SI PhotosWe handpicked some of our favorite shots from over the decades. Ohio State Vs. Michigan: Looking Back on ‘The Spot,’ Five Years OnIn the ...

Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

Using one of the best photo storage and sharing sites is vital if you have lots of photos. Whether you’re a pro photographer, an avid enthusiast or just like taking lots of casual pictures ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...